American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Document Recognizes … | Your money


RICHLAND, Wash., September 28, 2021 (GLOBE NEWSWIRE) – The American Brachytherapy Society (ABS) has recognized Isoray’s cesium-131 ​​in its newly released consensus statement on the subject of prostate brachytherapy at low dose rate (LDR). This is the first time that cesium-131 ​​has been included in ABS’s well-respected consensus guidelines. Because cesium-131 ​​seeds were not available as a treatment until 2004, long-term results after cesium-131 ​​prostate brachytherapy seeds have only recently become available.

The ABS does not classify or endorse any specific treatment option, but rather focuses on evaluating the evidence and providing insight into the research surrounding the use of brachytherapy in the treatment of malignancies and benign.

Reacting to the new evidence-based consensus statement, Isoray CEO Lori Woods underscored the importance of this milestone. Woods said, “We are honored that this prestigious organization has included Isoray Cesium-131 ​​in these consensus guidelines. This is another important step forward as we continue to innovate and strengthen our position as a leader in prostate brachytherapy. “

Entitled, Low Dose Rate Brachytherapy for the Primary Treatment of Localized Prostate Cancer: A Systemic Review and Summary of an Evidence-Based Consensus Statement, the findings are a “guideline intended to present based consensus recommendations. on evidence for permanent low dose rate (LDR) seed brachytherapy for the treatment of prostate cancer. The document was the result of the work of a working group on ABS. According to the ABS Working Group, the results of their extensive review of the literature led them to declare that LDR prostate brachytherapy monotherapy is an appropriate treatment option for low-risk and favorable intermediate-risk diseases. In combination with external radiation, he has also found that LDR brachytherapy is suitable for the adverse treatment of intermediate-risk and high-risk prostate cancer.

Cesium-131 ​​has the shortest half-life and the highest energy level of the radioisotopes currently recommended by ABS for LDR brachytherapy for the treatment of prostate cancer. The energy of cesium-131 ​​is powerful, allowing it to aggressively attack the treated cancer. Its shorter half-life means the radiation delivers its treatment dose faster, reducing other patient problems that can arise from prolonged radiation exposure. The rapid resolution of side effects is an important benefit for patients, allowing them to quickly return to normal life.

Isoray is a medical technology company and an innovator in the field of seed brachytherapy, offering expanding treatment options throughout the body. The company is the world’s only producer of cesium-131 ​​brachytherapy, which treats prostate cancer and extends internal radiation therapy for difficult-to-treat cancers of the brain, lung, gynecologic, head and neck, pelvic and colorectal .

About Isoray Isoray, Inc. is a pioneering medical technology company in advanced treatment applications and devices to provide targeted internal radiation therapy for cancers throughout the body. Isoray, Inc., through its subsidiary Isoray Medical, Inc., is the sole producer of cesium-131 ​​brachytherapy seeds. Learn more about this innovative company from Richland, Washington and explore the many benefits and uses of cesium-131 ​​by visiting www.isoray.com. Follow us on LinkedIn and Twitter

Media and Public Relations Contact: Sharon Schultz (302) 539-3747 Investor Relations: Mark Levin (501) 255-1910

Ford to create 10,800 electric vehicle and battery manufacturing jobs

Copyright 2021 GlobeNewswire, Inc.

Previous China Airshow Announces Rise of National Defense Industry
Next Amplience Named a 2021 IDC MarketScape Leader in Content Management Systems for Persuasive Digital Experiences